Education
About Us
Working with TipRanks
Follow Us
Teva Pharmaceutical (TEVA)
NYSE:TEVA
TEVA Stock Chart & Stats
$24.26
$0.18(0.83%)
At close: 4:00 PM EST
$24.26
$0.18(0.83%)
Day’s Range― - ―
52-Week Range$12.47 - $25.00
Previous CloseN/A
Volume1.13M
Average Volume (3M)11.53M
Market Cap
$27.81B
Enterprise Value$38.39B
Total Cash (Recent Filing)$2.20B
Total Debt (Recent Filing)$17.07B
Price to Earnings (P/E)39.1
Beta0.49
Next Earnings
Feb 11, 2026EPS Estimate
0.67Last Dividend Ex-Date
Nov 27, 2017Dividend YieldN/A
Share Statistics
EPS (TTM)0.78
Shares Outstanding1,146,838,700
10 Day Avg. Volume16,622,661
30 Day Avg. Volume11,532,676
Financial Highlights & Ratios
PEG Ratio-0.08
Price to Book (P/B)4.63
Price to Sales (P/S)1.51
P/FCF Ratio33.28
Enterprise Value/Market Cap1.38
Enterprise Value/Revenue2.29
Enterprise Value/Gross Profit4.57
Enterprise Value/Ebitda14.98
Forecast
1Y Price Target
$29.20Price Target Upside20.36% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Commercial OpportunitiesThe CEO remains bullish on the commercial opportunity for Olanzapine LAI underpinned by strength of profile and lack of alternatives.
Credit RatingManagement expressed a high degree of confidence in achieving an IG credit rating by 2H26.
Financial GuidanceThe company reaffirmed FY25 guidance and raised product-level guide for key growth brands.
Bears Say
Product PerformanceUS generics missed forecast, mainly due to lower g-Revlimid contribution.
Teva Pharmaceutical News
TEVA FAQ
What was Teva Pharmaceutical’s price range in the past 12 months?
Teva Pharmaceutical lowest stock price was $12.46 and its highest was $25.00 in the past 12 months.
What is Teva Pharmaceutical’s market cap?
Teva Pharmaceutical’s market cap is $27.81B.
When is Teva Pharmaceutical’s upcoming earnings report date?
Teva Pharmaceutical’s upcoming earnings report date is Feb 11, 2026 which is in 92 days.
How were Teva Pharmaceutical’s earnings last quarter?
Teva Pharmaceutical released its earnings results on Nov 05, 2025. The company reported $0.78 earnings per share for the quarter, beating the consensus estimate of $0.69 by $0.09.
Is Teva Pharmaceutical overvalued?
According to Wall Street analysts Teva Pharmaceutical’s price is currently Undervalued.
Does Teva Pharmaceutical pay dividends?
Teva Pharmaceutical pays a Quarterly dividend of $0.085 which represents an annual dividend yield of N/A. See more information on Teva Pharmaceutical dividends here
What is Teva Pharmaceutical’s EPS estimate?
Teva Pharmaceutical’s EPS estimate is 0.67.
How many shares outstanding does Teva Pharmaceutical have?
Teva Pharmaceutical has 1,146,838,700 shares outstanding.
What happened to Teva Pharmaceutical’s price movement after its last earnings report?
Teva Pharmaceutical reported an EPS of $0.78 in its last earnings report, beating expectations of $0.69. Following the earnings report the stock price went up 20.235%.
Which hedge fund is a major shareholder of Teva Pharmaceutical?
Currently, no hedge funds are holding shares in TEVA
Teva Pharmaceutical Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Price Target Potential
57.35% Upside
Analyst Consensus
Strong Buy
Average Price Target:
$29.20 (20.36% Upside)
$29.20 (20.36% Upside)
Blogger Sentiment
Bullish
TEVA Sentiment 87%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 3.0M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $5.1M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Neutral
Last 7 Days ▼ 0.2%
Last 30 Days ▲ 1.1%
Last 30 Days ▲ 1.1%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
36.97%
12-Months-Change
Fundamentals
Return on Equity
10.77%
Trailing 12-Months
Asset Growth
-4.55%
Trailing 12-Months
Company Description
Teva Pharmaceutical
Teva Pharmaceutical Industries Ltd. is a global leader in generic and specialty pharmaceuticals, headquartered in Petah Tikva, Israel. The company primarily operates in two segments: Generics, which includes a broad portfolio of generic medicines across various therapeutic areas, and Specialty, which focuses on complex and innovative medications, including branded drugs for neurological and respiratory conditions. Teva's extensive product range includes active pharmaceutical ingredients (APIs) and over-the-counter (OTC) products, positioning it as a vital player in the global healthcare landscape.
TEVA Company Deck
TEVA Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
Teva demonstrated strong growth in its innovative portfolio and significant debt reduction, reinforcing confidence in long-term targets. However, challenges remain in the TAPI segment, European generics, and declining free cash flow, which offset some of the positive developments.View all TEVA earnings summariesTEVA Revenue Breakdown
54.45% North America
32.42% Europe
13.12% International Markets
TEVA Stock 12 Month Forecast
Average Price Target
$29.20
▲(20.36% Upside)
Technical Analysis
Dr Reddy's Laboratories
―
Viatris
―
Neurocrine
―
Perrigo Company
―
Amneal Pharmaceuticals
―
Ownership Overview
0.43% Insiders
6.78% Mutual Funds
0.74% Other Institutional Investors
88.18% Public Companies and Individual Investors